Arcturus therapeutics to report third quarter 2021 financial results and provide corporate update on november 8, 2021

San diego--(business wire)--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a leading clinical-stage messenger rna medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the third quarter ended september 30, 2021 after the market close on monday november 8, and will also host a conference call and webcast at 4:30 pm eastern standard time on november 8, 2021. monday, november 8th @ 4:30 p.m. est domestic: 877-407-0784 international: 201-689-8560 conference id: 13724305 webcast: https://78449.themediaframe.com/dataconf/productusers/vvdb/mediaframe/47084/indexl.html about arcturus therapeutics founded in 2013 and based in san diego, california, arcturus therapeutics holdings inc. (nasdaq: arct) is a clinical-stage mrna medicines and vaccines company with enabling technologies: (i) lunar® lipid-mediated delivery, (ii) starr™ mrna technology and (iii) mrna drug substance along with drug product manufacturing expertise. arcturus’ diverse pipeline of rna therapeutic and vaccine candidates includes mrna vaccine programs for sars-cov-2 (covid-19) and influenza, and other programs to potentially treat ornithine transcarbamylase (otc) deficiency, and cystic fibrosis along with partnered programs including glycogen storage disease type iii, hepatitis b virus, and non-alcoholic steatohepatitis (nash). arcturus’ versatile rna therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger rna, small interfering rna, replicon rna, antisense rna, microrna, dna, and gene editing therapeutics. arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the u.s., europe, japan, china and other countries). arcturus’ commitment to the development of novel rna therapeutics has led to collaborations with janssen pharmaceuticals, inc., part of the janssen pharmaceutical companies of johnson & johnson, ultragenyx pharmaceutical, inc., takeda pharmaceutical company limited, curevac ag, synthetic genomics inc., duke-nus medical school, and the cystic fibrosis foundation. for more information visit www.arcturusrx.com. in addition, please connect with us on twitter and linkedin.
ARCT Ratings Summary
ARCT Quant Ranking